Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single-arm, prospective phase II trial (RIFLE). A phase 1 dose ...
Median progression-free survival (PFS) improved from 23 months with surgery alone to 25 months with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC), a nonsignificant difference. Post ...
Adding hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery significantly improved overall survival (OS) in women with platinum-sensitive, recurrent epithelial ovarian carcinoma, ...
A phase 1 dose escalation study of a novel coupled CAR T cell therapy, GCC19CART, for patients with metastatic colorectal cancer. A new prognostic tool for metastatic colorectal cancer patients ...
CRS-HIPEC stands for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. It’s pronounced “high-peck.” This treatment is for people with cancer that has spread to the lining of the ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Please provide your email address to receive an email when new articles are posted on . In this video, Robert DeBernardo, MD, discusses his research on hyperthermic intraperitoneal chemotherapy among ...
SCS combined with HIPEC may improve overall survival in PSROC patients compared to SCS alone, with a statistically significant benefit observed. The risk of severe complications, including anemia and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results